DK1023074T3 - Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion - Google Patents

Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion

Info

Publication number
DK1023074T3
DK1023074T3 DK98950911T DK98950911T DK1023074T3 DK 1023074 T3 DK1023074 T3 DK 1023074T3 DK 98950911 T DK98950911 T DK 98950911T DK 98950911 T DK98950911 T DK 98950911T DK 1023074 T3 DK1023074 T3 DK 1023074T3
Authority
DK
Denmark
Prior art keywords
methods
glucocorticoid
psychosis associated
treating psychosis
related dysfunction
Prior art date
Application number
DK98950911T
Other languages
Danish (da)
English (en)
Inventor
Alan F Schatzberg
Joseph K Belanoff
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1023074T3 publication Critical patent/DK1023074T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98950911T 1997-10-06 1998-10-05 Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion DK1023074T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06

Publications (1)

Publication Number Publication Date
DK1023074T3 true DK1023074T3 (da) 2006-11-06

Family

ID=22032889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98950911T DK1023074T3 (da) 1997-10-06 1998-10-05 Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion

Country Status (17)

Country Link
US (2) US6150349A (ko)
EP (1) EP1023074B1 (ko)
JP (3) JP2001518509A (ko)
KR (2) KR100804558B1 (ko)
CN (3) CN1528315A (ko)
AT (1) ATE332696T1 (ko)
AU (1) AU747956B2 (ko)
CA (1) CA2302586C (ko)
CY (1) CY1106330T1 (ko)
DE (1) DE69835225T2 (ko)
DK (1) DK1023074T3 (ko)
ES (1) ES2268792T3 (ko)
IL (2) IL135469A0 (ko)
NO (1) NO327233B1 (ko)
NZ (1) NZ503250A (ko)
PT (1) PT1023074E (ko)
WO (1) WO1999017779A1 (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
DE60124289T2 (de) * 2000-09-18 2007-09-06 Applied Research Systems Ars Holding N.V. Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
CA2440605C (en) * 2001-03-23 2012-01-10 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
NZ529456A (en) * 2001-05-04 2005-10-28 Corcept Therapeutics Inc Use of GR antagonists such as RU009 and RU044 to ameliorate the symptoms of delirium
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
NZ530724A (en) * 2001-07-23 2005-09-30 Corcept Therapeutics Inc Methods for preventing antipsychotic-induced weight gain
ES2314103T3 (es) * 2001-08-31 2009-03-16 Corcept Therapeutics, Inc. Metodo para inhibir deterioro cognitivo en adultos con sindrome de down.
HUP0500070A3 (en) * 2001-10-26 2012-09-28 Pop Test Cortisol Llc Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
EP1534299A4 (en) * 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
WO2004069202A2 (en) * 2003-02-04 2004-08-19 Corcept Therapeutics, Inc Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
WO2006060736A2 (en) * 2004-12-03 2006-06-08 The Children's Hospital Of Philadelphia A composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
CN100588393C (zh) * 2004-12-15 2010-02-10 上海三合生物技术有限公司 赛米司酮类用于治疗抑郁症的用途
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
CA2649894A1 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
AU2008265898B2 (en) * 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
ES2762243T3 (es) * 2010-05-26 2020-05-22 Corcept Therapeutics Inc Tratamiento de distrofia muscular
JP5804395B2 (ja) * 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3265127B1 (en) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US10604807B2 (en) 2015-05-18 2020-03-31 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for Cushing's syndrome
WO2018074371A1 (ja) * 2016-10-21 2018-04-26 シチズン時計株式会社 検出装置
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
WO1997037664A2 (en) * 1996-04-09 1997-10-16 British Technology Group Ltd. Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Also Published As

Publication number Publication date
JP5180125B2 (ja) 2013-04-10
CY1106330T1 (el) 2011-10-12
ES2268792T3 (es) 2007-03-16
KR100804558B1 (ko) 2008-02-20
KR20010024431A (ko) 2001-03-26
CN1187053C (zh) 2005-02-02
NO20001744L (no) 2000-04-05
CN1528315A (zh) 2004-09-15
EP1023074B1 (en) 2006-07-12
CA2302586C (en) 2008-06-10
DE69835225T2 (de) 2007-07-05
US6362173B1 (en) 2002-03-26
KR20070032822A (ko) 2007-03-22
AU747956B2 (en) 2002-05-30
US6150349A (en) 2000-11-21
WO1999017779A1 (en) 1999-04-15
NO327233B1 (no) 2009-05-18
NZ503250A (en) 2001-09-28
IL135469A (en) 2007-03-08
AU9683298A (en) 1999-04-27
JP2009051858A (ja) 2009-03-12
EP1023074A1 (en) 2000-08-02
IL135469A0 (en) 2001-05-20
JP2009132743A (ja) 2009-06-18
CA2302586A1 (en) 1999-04-15
CN1919199A (zh) 2007-02-28
PT1023074E (pt) 2006-12-29
KR100840957B1 (ko) 2008-06-24
DE69835225D1 (de) 2006-08-24
ATE332696T1 (de) 2006-08-15
NO20001744D0 (no) 2000-04-05
CN1272788A (zh) 2000-11-08
JP2001518509A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
DK1023074T3 (da) Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
NO20031179D0 (no) Chemokin-reseptorbindende heterocykliske forbindelser
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
AUPO755097A0 (en) Receptor agonist and antagonist
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
DK0946189T3 (da) Anvendelse af aktivatorer af CNTF (ciliær neurotrofisk faktor) receptor til behandling af adipositas
PT1066380E (pt) Receptor de celula t soluvel
EP1351670A4 (en) METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS
CY1110828T1 (el) Τροποποιημενοι πυριμιδινικοι ρυθμιστες του γλυκοκορτικοειδους υποδοχεα
DE69533180D1 (de) Steroidrezeptor-Modulator Verbindungen und Methoden
WO2007027734A3 (en) Bicyclic and bridged nitrogen heterocycles
HK1068783A1 (en) Methods for increasing the therapeutic response to electroconvulsive therapy ("ect")
ECSP056254A (es) Antagonistas de receptores muscarínicos de la acetilcolina
CL2004000545A1 (es) Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
HK1032535A1 (en) Glucocorticoid receptor antagonists for the treatment of dementia
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
HUP0201184A3 (en) Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
NO994850L (no) Farmakologiske midler
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
SV2002000005A (es) Heterociclos 2-arilimino substituidos y composiciones que los contienen para usar como agentes que ligan el receptor de la progesterona ref. 5048p1-sv
ATE411013T1 (de) Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
DE69803883D1 (de) Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren